Sun Pharma Advanced Research Company Limited
NSE: SPARC
Employs 279 permanent employees and workers, −11.7% on the year before, as filed for the year to 31 Mar 2026 on a group basis. Revenue in the quarter to 31 Dec 2024 was ₹15 cr.
Headcount
Annual, from the BRSR filed with NSE (as of 31 March each year)
| As of | Scope | Permanent | Change (%) | Contract / other | Change (%) |
|---|---|---|---|---|---|
| 31 Mar 2023 | Standalone | 407 | — | 172 | — |
| 31 Mar 2024 | Group⚠ | 409 | 2(0.5%) | 194 | 22(12.8%) |
| 31 Mar 2025 | Group | 316 | −93(22.7%) | 196 | 2(1.0%) |
| 31 Mar 2026 | Group | 279 | −37(11.7%) | 187 | −9(4.6%) |
- ⚠The reporting scope changed from the previous period, so the two are not comparable.
Permanent = permanent employees + permanent workers, as defined in SEBI's BRSR. "Standalone" figures cover the listed company alone and exclude its subsidiaries.
Financials (₹ cr)
| Period | Revenue (₹ cr) | Change (%) | Employee cost (₹ cr) | Change (%) | Net profit (₹ cr) | Change (%) | Flags |
|---|---|---|---|---|---|---|---|
| Quarter ended 31 Dec 2024 | 15 | 2(15.9%) | 26 | −2(8.2%) | -80 | 28(26.0%) | |
| Quarter ended 30 Sept 2024 | 13 | −4(23.5%) | 29 | −0(0.5%) | -108 | −11(11.2%) | |
| Quarter ended 30 Jun 2024 | 17 | 0(1.5%) | 29 | 2(8.3%) | -97 | 10(9.2%) | |
| Quarter ended 31 Mar 2024 | 17 | 3(19.5%) | 27 | −3(10.9%) | -107 | −7(7.1%) | |
| Quarter ended 31 Dec 2023 | 14 | −7(34.6%) | 30 | −1(2.4%) | -100 | −13(15.3%) | |
| Quarter ended 30 Sept 2023 | 21 | −3(11.6%) | 31 | −0(1.3%) | -86 | 9(9.4%) | |
| Quarter ended 30 Jun 2023 | 24 | −24(49.8%) | 31 | 1(4.1%) | -95 | −13(16.3%) | |
| Quarter ended 31 Mar 2023 | 48 | −83(63.6%) | 30 | 4(16.5%) | -82 | −92(907.8%) | |
| Quarter ended 31 Dec 2022 | 131 | 106(419.4%) | 26 | 3(11.2%) | 10 | 81(114.3%) | |
| Quarter ended 31 Mar 2022 | 25 | −37(59.4%) | 23 | −1(4.8%) | -71 | −55(348.6%) | ⚠ |
| Quarter ended 31 Dec 2021 | 62 | 34(123.0%) | 24 | 0(1.3%) | -16 | 39(71.3%) | ⚠ |
| Quarter ended 30 Sept 2021 | 28 | 6(26.7%) | 24 | −2(6.2%) | -55 | 6(10.2%) | ⚠ |
| Quarter ended 30 Jun 2021 | 22 | −6(21.6%) | 26 | 3(15.5%) | -61 | −5(8.2%) | ⚠ |
| Quarter ended 31 Mar 2021 | 28 | 6(28.7%) | 22 | −1(2.4%) | -57 | 11(16.1%) | ⚠ |
| Quarter ended 31 Dec 2020 | 22 | 4(23.6%) | 23 | −0(0.8%) | -68 | 16(19.0%) | ⚠ |
| Quarter ended 30 Sept 2020 | 18 | −168(90.5%) | 23 | −1(4.9%) | -83 | −140(247.3%) | ⚠ |
| Quarter ended 30 Jun 2020 | 185 | 163(716.6%) | 24 | −0(1.6%) | 57 | 156(156.9%) | ⚠ |
| Quarter ended 31 Mar 2020 | 23 | 3(15.9%) | 24 | 2(7.1%) | -100 | −44(79.3%) | ⚠ |
| Quarter ended 31 Dec 2019 | 20 | 2(14.0%) | 23 | −1(2.2%) | -56 | 8(12.1%) | ⚠ |
| Quarter ended 30 Sept 2019 | 17 | −0(0.8%) | 23 | 1(2.7%) | -63 | 31(32.9%) | ⚠ |
| Quarter ended 30 Jun 2019 | 17 | −68(79.6%) | 23 | 3(17.3%) | -94 | −85(907.4%) | ⚠ |
| Quarter ended 31 Mar 2019 | 85 | 65(326.7%) | 19 | −2(9.5%) | -9 | 60(86.5%) | ⚠ |
| Quarter ended 31 Dec 2018 | 20 | −41(67.6%) | 21 | 1(7.1%) | -69 | −66(2575.2%) | ⚠ |
| Quarter ended 30 Sept 2018 | 61 | 45(265.0%) | 20 | −0(2.4%) | -3 | 62(96.0%) | ⚠ |
| Quarter ended 30 Jun 2018 | 17 | −3(16.3%) | 20 | −4(15.9%) | -64 | −67(2700.0%) | ⚠ |
| Quarter ended 31 Mar 2018 | 20 | — | 24 | — | 2 | — | ⚠ |